Biomarker Discovery in Cardio-Oncology.

Area of Science:

• Cardio-oncology
• Biomarker Discovery
• Cardiovascular Toxicity

Background:

• Established biomarkers like troponins and brain natriuretic peptide show potential but lack sufficient evidence for routine use in monitoring cancer therapy-associated cardiotoxicity.
• Preclinical research and "omics" techniques are identifying novel candidate biomarkers for early cancer therapy-induced cardiovascular toxicity detection.

Purpose of the Study:

• To review current and emerging strategies for biomarker discovery in early diagnosis of cancer therapy-associated cardiovascular toxicity.
• To highlight the potential of new biomarkers to improve risk stratification and patient outcomes in cardio-oncology.

Main Methods:

• Review of preclinical studies on molecular mechanisms of cardiotoxicity.
• Analysis of "omics" techniques applied to small patient cohorts for biomarker identification.

Main Results:

• Small studies indicate associations between cardiac injury biomarkers and cardiotoxicity, but clinical validation is pending.
• Promising candidate biomarkers have emerged from "omics" platforms, requiring further validation in large patient cohorts.

Conclusions:

• Novel biomarkers hold significant potential for improving early diagnosis and management of cardiotoxicity in cancer patients.
• Further research, including large-scale validation studies, is crucial before integrating new biomarkers into clinical practice for cardio-oncology.